Steven C. Eror is no longer serving in their position at ProLung, Inc.
Jul 02, 2018
Board and Executive Moves
Founder at ProLung, Inc.
In The News
ProLung Shareholder Group Receives More Than The Requisite Number Of Consents To Enlarge And Enhance The Board
Sep 28, 2018 - PR Newswire
ProLung Shareholder Group Urges Shareholders To Ignore The Company's GOLD Consent Revocation Card And Instead Consent To Enlarge And Enhance The Board Using Its WHITE Consent Card
Sep 12, 2018 - PR Newswire
IONIQ Sciences, Inc. is a medical technology company, which specializes in predictive analytics technology, early stage lung cancer risk testing. It develops, tests and commercializes solutions which are designed to accelerate the time to diagnosis and expand the therapeutic window for lung cancer patients. Its product under the name of ProLung Test was developed to assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography scan. The company was founded by Steven C. Eror on November 19, 2004 and is headquartered in Salt Lake City, UT.
In The News
Oct 20, 2020 - ENP Newswire
Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Oct 05, 2020 - GlobeNewswire
Sep 16, 2020 - SEC